VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

Core Insights - VYNE Therapeutics Inc. has initiated a Phase 1b trial for VYN202, an oral small molecule BET inhibitor, targeting moderate-to-severe plaque psoriasis, marking a significant advancement in its clinical development [1][2][3] - The trial aims to evaluate the safety, tolerability, and pharmacokinetics of VYN202 over a 12-week period, with top-line data expected by the end of 2025 [1][3][6] Company Overview - VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory and immune-mediated conditions with high unmet needs [9] - The company’s proprietary BET inhibitors, including VYN202, are designed to overcome limitations of earlier generation BET inhibitors through enhanced selectivity and alternative administration routes [9] Product Details - VYN202 is characterized as a highly selective oral BET inhibitor with potential advantages in treating immune-mediated diseases due to its class-leading selectivity for BD2 over BD1 [5][6] - The Phase 1b trial will include three dosing cohorts (0.25 mg, 0.5 mg, 1 mg) and will assess exploratory efficacy measures such as PASI scores and quality of life [3][4] Disease Context - Plaque psoriasis is a chronic immune-mediated disease affecting over 8 million Americans and more than 125 million people globally, characterized by inflamed, scaly plaques [4] - The disease shares common inflammatory pathways with other chronic conditions, suggesting potential broader applications for VYN202 in treating various immune-mediated diseases [4][2]